Pesquisar Neste Blog

terça-feira, 7 de junho de 2011

Veterinary Anaesthesia and Analg... Content Alert (New Articles)


Veterinary Anaesthesia and Analgesia

Cover image for Vol. 38 Issue 3

Early View (Online Version of Record published before inclusion in an issue)

Edited By: KW Clarke and Peter Pascoe
Impact Factor: 1.426
ISI Journal Citation Reports © Ranking: 2009: 35/141 (Veterinary Sciences)
Online ISSN: 1467-2995
  1. Research Papers

    1. You have full text access to this content
      Patricia Krohm, Olivier Levionnois, Murielle Ganster, Luca Zilberstein and Claudia Spadavecchia
      Article first published online: 6 JUN 2011 | DOI: 10.1111/j.1467-2995.2011.00623.x
    2. You have full text access to this content
      Luiz Cesar P Santos, John W Ludders, Hollis N Erb, Manuel Martin-Flores, Karen L. Basher and Pati Kirch
      Article first published online: 6 JUN 2011 | DOI: 10.1111/j.1467-2995.2011.00619.x
    3. You have full text access to this content
      Kerstin Müller, Judith Holzapfel and Leo Brunnberg
      Article first published online: 3 JUN 2011 | DOI: 10.1111/j.1467-2995.2011.00624.x
    4. You have full text access to this content
      Tatiana H. Ferreira, Eugene P. Steffey, Khursheed R. Mama, Marlis L. Rezende and Antonio J. A. Aguiar
      Article first published online: 1 JUN 2011 | DOI: 10.1111/j.1467-2995.2011.00618.x
    5. You have full text access to this content
      Vivianne H Imagawa, Denise T Fantoni, Angélica C Tatarunas, Sandra Mastrocinque, Tatiana F Almeida, Fernando Ferreira and Irimar P Posso
      Article first published online: 1 JUN 2011 | DOI: 10.1111/j.1467-2995.2011.00617.x
    6. You have full text access to this content
      Lydia Love, Christine Egger, Barton Rohrbach, Sherry Cox, Meredith Hobbs and Thomas Doherty
      Article first published online: 1 JUN 2011 | DOI: 10.1111/j.1467-2995.2011.00616.x
    7. You have full text access to this content
      Andre Shih, Steeve Giguère, Alessio Vigani, Renata Shih, Naveen Thuramalla and Carsten Bandt
      Article first published online: 1 JUN 2011 | DOI: 10.1111/j.1467-2995.2011.00604.x
    8. You have full text access to this content
    9. You have full text access to this content
      Manuel Martin-Flores, Eileen J Lau, Luis Campoy, Hollis N Erb and Robin D Gleed
      Article first published online: 1 JUN 2011 | DOI: 10.1111/j.1467-2995.2011.00620.x
    10. You have full text access to this content
      Kristen M Messenger, Jennifer L Davis, Douglas H LaFevers, Beth M Barlow and Lysa P Posner
      Article first published online: 19 APR 2011 | DOI: 10.1111/j.1467-2995.2011.00613.x

Scientists Uncover Role for Cell Scaffold in Tumor Formation: Fruit Fly Reveals Surprising Link

ScienceDaily (June 6, 2011) — A group of scientists at the Instituto Gulbenkian de Ciência, in Portugal, has uncovered a surprising link between the cell's skeleton and organ size. The team, led by Florence Janody, shows in the journal Development, that one of the proteins that regulates the skeleton of the cell also acts to blocks activation of genes that promote cell survival and proliferation. Their findings have implications for cancer research, as they add to the puzzle of understanding how proliferation genes are abnormally activated, often leading to tumours.
In normal tissue, with an intact cytoskeleton (in purple), the Hippo complex blocks the Yorkie protein (Yki, in green) from activating proliferation genes in the nucleus (image on the left). When the cytoskeleton is deregulated, Yorkie is free to enter the nucleus and activate proliferation of the cell (image on the right). 
During development of an embryo, cells proliferate and organs grow. This process is tightly regulated, at several levels, to ensure that organs do not outgrow the body they are in. One of the key regulators in this process is the Hippo complex of proteins -- first identified in the fruit fly Drosophila melanogaster. Mutant flies, in which this complex is defective are larger than their counterparts -- they are hippopotamus-like. A search for analogous genes uncovered a similar role for the Hippo complex in mammals -- organs grow larger than they should. In adults, this abnormal and untimely growth often leads to tumour formation.

A flurry of papers has shown that the Hippo complex itself is regulated by a range of signaling inputs within the cell. Florence Janody's group identified a new, and unexpected input: the cell skeleton (called cytoskeleton), in particular one of its proteins, the actin-capping protein.

Using Drosophila larvae, the IGC team showed that when the actin-capping proteins are inactive, there is overgrowth of tissue in the area that will become the adult wing. This growth is reminiscent of tumour formation. The researchers dissected the different steps in the process that lead to abnormal growth. Inactivating actin-capping proteins leads to accumulation of actin, a major component of the cytoskeleton; this reduces the activity of the Hippo complex, leaving another protein, Yorkie, free to act on the DNA in the nucleus, turning on proliferation genes.

The cytoskeleton serves several functions in a cell: it provides structure, motility (allows cells to move, change shape and divide) and membrane traffic (transport of proteins and other large molecules within the cell). The actin protein forms cables that crisscross the cell. The cables are constantly being elongated and shortened at their ends. The actin-capping proteins are involved in this process.

In Florence's words, ' What we've revealed is that the cytoskeleton needs to be very tightly regulated within the cell, to prevent abnormal growth in the larvae. Since Hippo is also turned on in the adult and in mammals, we believe these findings provide insights into how this process may be manipulated in human cells, with a view to preventing tumour formation, or blocking its progression'.

New Strategy to Attack Tumor-Feeding Blood Vessels

ScienceDaily (June 6, 2011) — Scientists at the Walter and Eliza Hall Institute have discovered a key molecule needed to kill the blood vessels that supply tumours.
Cancers such as breast cancer, lung cancer and melanoma release the blood vessel growth factor, VEGF, to encourage blood vessels to grow within the tumor, supplying it with nutrients. Tumors can be treated with anti-cancer medications that kill the cancer cells, and anti-angiogenic medications that starve the tumour by attacking its blood supply. The study suggests that a third type of medication, BH3-mimetics, may enhance the tumor-killing effect of anti-cancer and anti-angiogenic medications.
The growth of solid tumours, such as lung cancer, breast cancer and melanoma, depends on nutrients and oxygen being provided by the tumour blood supply. Cancer cells encourage the growth of blood vessels to feed a tumour by producing the hormone-like protein, vascular endothelial growth factor (VEGF). The research by Drs Edwina Naik, Leigh Coultas and Lorraine O'Reilly, and Professors Jerry Adams and Andreas Strasser showed that VEGF produced by tumours blocks production of Bim in the cells that line the tumour blood vessels.The research team from the institute's Molecular Genetics of Cancer and Cancer and Haematology divisions found that for anti-cancer therapies that target tumour blood vessels to work the death- inducing molecule Bim is required. The finding could lead to improved anti-cancer treatments that are based on a two- or three-pronged attack on both the tumour and its blood supply. The research will be published online in the Journal of Experimental Medicine.

New 'anti-angiogenic' medications that attack the blood vessels within tumours are showing promise in starving many types of cancers by reducing their blood supply.

In this study, in experimental melanoma, lung cancer and breast cancer models, Bim levels increased in the cells lining the blood vessels when VEGF was depleted by anti-angiogenic drugs, ultimately killing the blood vessel cells. VEGF depletion reduced the number of blood vessels in tumours, making the tumours shrink. However, in mice in which the blood vessels do not express Bim, VEGF depletion did not affect the number of tumour-associated blood vessels, and tumours grown in Bim-deficient mice did not respond to anti-angiogenic treatments.

Dr Strasser said this finding suggests that strategies for treating tumours by attacking the tumour blood supply could be optimised by incorporating drugs called BH3-mimetics that cause cell death by acting like Bim at a molecular level. "Similarly, therapies that increase the amount of Bim in tumour blood vessels could enhance the effects of anti-angiogenic agents," Dr Strasser said.

"BH3 mimetics may have two beneficial effects in cancer therapy. Our previous research had showed they can directly trigger death in tumour cells, particularly when the tumour is also attacked by chemotherapeutic drugs. We now think BH3-mimetics could also impact tumour cells indirectly by killing endothelial cells within tumours.

"This suggests that a promising new approach to the therapy of solid tumours may be to use a three-medication combination of a drug that specifically targets the tumour cell, an anti- angiogenic agent to impair the tumour blood vessels, plus a BH3 mimetic that will help the anti- tumour drug to directly kill the tumour cells and also will help the anti-angiogenic agent to kill the intra-tumoral endothelial cells, which in turn will starve the tumour, causing even more tumour cell death."

The research was supported by the Cancer Council Victoria, the National Health and Medical Research Council, the Australian Research Council, the US National Institutes of Health, the Leukemia and Lymphoma Society and Genentech.

Insulin Action in the Brain Can Lead to Obesity: How Insulin in Hypothalamus Controls Body's Energy Balance

ScienceDaily (June 6, 2011) — Fat-rich food makes you fat. Behind this simple equation lie complex signalling pathways, through which the neurotransmitters in the brain control the body's energy balance. Scientists at the Cologne-based Max Planck Institute for Neurological Research and the Cluster of Excellence in Cellular Stress Responses in Ageing-associated Diseases (CECAD) at the University of Cologne have clarified an important step in this complex control circuit. They have succeeded in showing how the hormone insulin acts in the part of the brain known as the ventromedial hypothalamus.
This is a visualization of how insulin affects the SF-1 neurons of the hypothalamus. After stimulation with insulin, the SF-1 cells (red) form the signaling molecule PiP3 (green). (Blue: cell nucleus)
The consumption of high-fat food causes more insulin to be released by the pancreas. This triggers a signalling cascade in special nerve cells in the brain, the SF-1 neurons, in which the enzyme P13-kinase plays an important role. Over the course of several intermediary steps, the insulin inhibits the transmission of nerve impulses in such a way that the feeling of satiety is suppressed and energy expenditure reduced. This promotes overweight and obesity.

The hypothalamus plays an important role in energy homeostasis: the regulation of the body's energy balance. Special neurons in this part of the brain, known as POMC cells, react to neurotransmitters and thus control eating behaviour and energy expenditure. The hormone insulin is an important messenger substance. Insulin causes the carbohydrate consumed in food to be transported to target cells (e.g. muscles) and is then available to these cells as an energy source. When high-fat food is consumed, more insulin is produced in the pancreas, and its concentration in the brain also increases. The interaction between the insulin and the target cells in the brain also plays a crucial role in the control of the body's energy balance. However, the precise molecular mechanisms that lie behind the control exercised by insulin remain largely unclear.

A research group led by Jens Brüning, Director of the Max Planck Institute for Neurological Research and scientific coordinator of the CECAD (Cellular Stress Responses in Aging-Associated Diseases) cluster of excellence at the University of Cologne has achieved an important step in the explanation of this complex regulatory process. As the scientists have shown, insulin in the SF-1 neurons -- another group of neurons in the hypothalamus -- triggers a signalling cascade. Interestingly, however, these cells appear only to be regulated by insulin when high-fat food is consumed and in the case of overweight. The enzyme P13-kinase plays a central role in this cascade of messenger substances. In the course of the intermediary steps in the process, the enzyme activates ion channels and thereby prevents the transmission of nerve impulses. The researchers suspect that the SF-1 cells communicate in this way with the POMC cells.

Kinases are enzymes that activate other molecules through phosphorylation -- the addition of a phosphate group to a protein or other organic molecule. "If insulin binds to its receptor on the surface of the SF-1 cells, it triggers the activation of the PI3-kinase," explains Tim Klöckener, first author of the study. "The PI3-kinase, in turn, controls the formation of PIP3, another signalling molecule, through phosphorylation. PIP3 makes the corresponding channels in the cell wall permeable to potassium ions." Their influx causes the neuron to 'fire' more slowly and the transmission of electrical impulses is suppressed.

"Therefore, in overweight people, insulin probably indirectly inhibits the POMC neurons, which are responsible for the feeling of satiety, via the intermediary station of the SF-1 neurons," supposes the scientist. "At the same time, there is a further increase in food consumption." The direct proof that the two types of neurons communicate with each other in this way still remains to be found, however.

In order to find out how insulin acts in the brain, the Cologne-based scientists compared mice that lacked an insulin receptor on the SF-1 neurons with mice whose insulin receptors were intact. With normal food consumption, the researchers discovered no difference between the two groups. This would indicate that insulin does not exercise a key influence on the activity of these cells in slim individuals. However, when the rodents were fed high-fat food, those with the defective insulin receptor remained slim, while their counterparts with functional receptors rapidly gained weight. The weight gain was due to both an increase in appetite and reduced calorie expenditure. This effect of insulin could constitute an evolutionary adaptation by the body to an irregular food supply and extended periods of hunger: if an excess supply of high-fat food is temporarily available, the body can lay down energy reserves particularly effectively through the action of insulin.

It is not currently possible to say whether the findings of this research will eventually help to facilitate targeted intervention in the body's energy balance. "We are currently still very far away from a practical application," says Jens Brüning. "Our objective is to find out how hunger and the feeling of satiety arise. Only when we understand the entire system at work here, we will be able to start developing treatments."